Q32 Bio
IPOBuilding the future of targeted immune therapeutics
Public · United States
- Employees
- 11–50
- Business Model
- B2B
- Website
- q32bio.com
- Last Round
- Series BDec 2020
- Rounds
- 2
- Type
- Public
About
Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of both the innate and adaptive immune systems with the goal of re-balancing immunity. The company is focused on discovering and developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Q32 Bio's lead product candidate, bempikibart (ADX-914), is a fully human anti-IL-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. The company is headquartered in Waltham, Massachusetts and trades on NASDAQ under the ticker QTTB.
Summary
Q32 Bio is a Healthcare company based in United States. Its most recent funding was a Series B round in Dec 2020. Investors include OrbiMed, Atlas Venture and Sanofi Ventures.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Largest private manufacturer and distributor of medical-surgical products serving healthcare prov...
Healthcare cost management company providing data analytics and network-based payment solutions t...
American dietary supplements company owning Nature's Bounty, Solgar, and Puritan's Pride brands; ...
China's leading blood products manufacturer
OneOncology empowers oncology practices with advanced tools and capabilities to help physicians d...
World-leading Canadian cannabis company cultivating and selling medicinal and recreational cannab...